Ketamine Troches vs. RDT Wafers: Understanding the Differences

When you compare a troche vs RDT for compounded ketamine, the core difference is speed and location of dissolution. A troche is a lozenge that dissolves slowly, over 10-20 minutes, in contact with mucosal tissue under the tongue or in the cheek. A rapidly dissolving tablet, or RDT, also called a wafer, orally disintegrating tablet, or ODT, dissolves in 30-60 seconds instead. Both formats use the same active ingredient, ketamine hydrochloride, but they differ in base material, handling, and the technique needed for consistent absorption. Understanding the troche vs RDT difference helps you use whichever formulation your pharmacy dispenses correctly, and helps you flag it if the format doesn't match what your provider intended to prescribe. For background on compounding, see our guide on how troches are made.

What Is a Troche?

A troche, also called a lozenge or pastille, is compounded to dissolve slowly, typically over 10-20 minutes. The base is usually polyethylene glycol (PEG), a solid matrix that softens and melts gradually in the mouth's warmth and moisture rather than dissolving on contact.

Troches are designed to:

• Maintain prolonged contact with mucosal surfaces
• Release ketamine gradually, allowing extended absorption time
• Provide a sustained therapeutic window rather than a rapid bolus

Because the PEG base melts rather than dissolving instantly, troches require the patient to stay still and hold the troche in position, usually under the tongue or in the cheek, for the full 10-20 minute dissolution period.

What Is an RDT or Wafer?

A rapidly dissolving tablet, or RDT, is built to dissolve almost instantly on contact with saliva, typically within 30-60 seconds. RDTs use fast-solubilizing excipients such as mannitol, sorbitol, microcrystalline cellulose, or freeze-dried (lyophilized) carriers instead of the PEG base used in troches. Ketamine hydrochloride's chemical and solubility properties, which inform how it's compounded into each base, are documented in PubChem, the National Institutes of Health's public chemistry database.

RDTs are used across pharmacy generally for:

• Pediatric medications, for patients who can't swallow pills
• Situations where faster dissolution improves convenience
• Oral drugs that benefit from brief mucosal contact before swallowing

For ketamine specifically, an RDT dissolves quickly, but how much drug is absorbed sublingually versus swallowed depends on what the patient does immediately afterward. If the dissolved dose is swallowed right away, most of it is absorbed through the gastrointestinal tract, where first-pass metabolism lowers bioavailability. If the patient holds the dissolved solution against the sublingual mucosa instead, absorption follows the same sublingual route as a troche.

Drug Release Profile

A troche releases ketamine progressively across its full dissolution period, creating an extended window of drug contact with mucosal tissue. An RDT releases ketamine almost immediately, producing a drug-rich saliva solution within seconds. Whether that dissolved ketamine is absorbed sublingually or swallowed depends on what the patient does next, not on the tablet format itself. For more on how release speed affects onset and duration, see our timeline of ketamine troche onset, peak, and duration.

Absorption Differences

Troche Absorption

The troche's slow dissolution keeps a drug-rich solution in contact with sublingual or buccal mucosa for the full 10-20 minute dissolution period, which maximizes the opportunity for mucosal absorption. The gradual release may also favor steadier drug concentration at the mucosal surface. Expected sublingual bioavailability from troches is approximately 20-30 percent. For more on how this compares to other oral routes, see our comparison of ketamine troches and oral capsules by bioavailability.

RDT Absorption

Because an RDT dissolves almost instantly, the absorbed fraction depends on what happens in the first few seconds after dissolution. If the patient holds the dissolved solution in the sublingual space without swallowing, mucosal absorption can occur. If saliva is swallowed promptly, the ketamine goes to the stomach and is absorbed enterally instead. According to StatPearls, a peer-reviewed clinical reference, orally swallowed ketamine undergoes substantial first-pass hepatic metabolism, which is why swallowed oral bioavailability runs closer to 16-20 percent, lower than the sublingual route.

In practice, RDTs compounded for ketamine are typically intended to be held in the mouth rather than swallowed right away. Some providers instruct patients to hold the dissolved RDT in the sublingual space for 1-5 minutes before, or instead of, swallowing. Bioavailability from ketamine RDTs depends heavily on technique: it can range from comparable to troches, about 20-30 percent, with careful technique, down to oral bioavailability levels if the dose is mostly swallowed.

Practical Handling Differences

Fragility

RDTs are significantly more fragile than troches. They can break, crumble, or begin dissolving from finger moisture during handling. Patients should:

• Handle RDTs carefully, moving them from packaging directly onto the tongue or into position with minimal finger contact
• Protect the tablet from humidity, since even touching it with damp fingers can start dissolution
• Keep RDTs in sealed packaging until the moment of use

Troches are sturdier and can be handled more normally during placement.

Technique Requirements

Troche: place under the tongue or in the buccal space, hold for 10-20 minutes while it dissolves, manage saliva, and stay still.

RDT: place under the tongue. The wafer dissolves within seconds. Then hold the dissolved solution against the sublingual mucosa without swallowing for the provider-specified duration, often 2-5 minutes.

The RDT technique may feel less cumbersome to some patients since there's no solid object to manage over an extended period. But the saliva-management challenge is similar either way: resist swallowing the dissolved drug for the specified hold time. For more on correct placement, see our guide to sublingual vs. buccal placement technique.

Which Does Your Provider Prescribe?

The choice between troches and RDTs is typically made by the prescriber or compounding pharmacy, based on:

• Provider preference: some providers have strong preferences based on clinical experience with patient outcomes
• Pharmacy capability: not all compounding pharmacies offer both formats, and some specialize in one or the other
• Patient factors: patients with dry mouth (xerostomia) may find troches dissolve poorly, making RDTs preferable, while patients with dexterity issues may find fragile RDTs harder to handle
• Dose: at higher doses, the troche base volume becomes larger, so very high doses may be compounded more practically as RDTs

If you receive RDTs when you expected troches, or the reverse, confirm with your pharmacy that the formulation matches your provider's prescription intent. The active ingredient, ketamine hydrochloride, and the dose should stay the same; only the formulation should differ. If you're unsure how to raise this with your provider, see our guide on working with your provider.

Clinical Outcome Differences

There is no large clinical trial directly comparing ketamine troche outcomes to RDT outcomes. In practice, clinicians who work with both formats report comparable results when patients are instructed correctly on technique. The variable that matters most in both cases is how much drug actually absorbs through the mucosa versus gets swallowed, and that depends more on patient technique than on the formulation itself.

If you switch between formulations, talk with your provider about the technique differences. You may need to adjust your approach, and your response to the medication may differ enough that your provider needs to revisit dose or frequency.